Close

Why I volunteered for a COVID-19 vaccine trial

Go back to Why I volunteered for a COVID-19 vaccine trial

Mizuho Securities Reiterates Buy Rating on Pfizer (PFE)

November 12, 2020 8:22 AM EST

Mizuho Securities analyst Vamil Divan reiterated a Buy rating and $44.00 price target on Pfizer (NYSE: PFE) following the company's COVID-19 vaccine data released on Monday. The COVID-19 data was eagerly anticipated by investors for obvious reasons.

The company has already secured commitments from... More